The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Fu, Xiaoyu ^a   Tan, Deming ^a   Hou, Zhouhua ^a   Hu, Zhiliang ^b   Liu, Guozhen ^a   Ouyang, Yi ^a   Liu, Fei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Nanjing Second Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; LIPOFECTAMINE; LUCIFERASE; MICRORNA; MICRORNA 338 3P; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AGAR MEDIUM; ARTICLE; BINDING SITE; CELL PROLIFERATION; CELL STRAIN HEPG2; COMPUTER ANALYSIS; CONTROLLED STUDY; DELETION MUTANT; DOWN REGULATION; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HEPATITIS B VIRUS X GENE; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REPORTER GENE; VIRUS GENE; WESTERN BLOTTING; WILD TYPE;

BLOTTING, WESTERN; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; CYCLIN D1; DNA PRIMERS; FLOW CYTOMETRY; HEPATITIS B VIRUS; HUMANS; LIPIDS; LIVER NEOPLASMS; LUCIFERASES; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE DELETION; TRANS-ACTIVATORS;

EID: 84865084970     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043204     Document Type: Article

References (54)

1. Murakami S, (2001) Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol 36: 651-660.
2. Venard V, Corsaro D, Kajzer C, Brnowicki JP, Le Fau A, (2000) Hepatitis B virus X gene variability in French-born patients with chronic hepatitis and hepatocellular carcinoma. J Med Virol 62: 177-84.
3. Zhu H, Wang Y, Chen J, Cheng G, Xue J, (2004) Transgenic mice expressing hepatitis B virus X protein are more susceptible to carcinogen induced hepatocarcinogenesis. Exp Mol Pathol 76: 44-50.
4. Tralhao JG, Roudier J, Morosan S, Giannini C, Tu H, et al. (2002) Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: an alternative mechanism of HBx-related pathogenesis. Proc Natl Acad Sci U S A 99: 6991-6996.
5. Wang JC, Hsu SL, Hwang GY, (2004) Inhibition of tumorigenicity of the hepatitis B virus X gene in Chang liver cell line. Virus Res 102: 133-139.
6. Minemura M, Shimizu Y, Hirano K, Nakayama Y, Tokimitsu Y, et al. (2005) Functional analysis of transactivation by mutants of hepatitis B virus X gene in human hepatocellular carcinoma. Oncol Rep JT-Oncology Reports 14: 495-499.
7. Yeh CT, Shen CH, Tai DI, Chu CM, Liaw YF, (2000) Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene JT-Oncogene 19: 5213-5220.
8. Sirmal H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, et al. (1999) Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 18: 4848-4859.
9. Iavarone M, Trabut JB, Delpuech O, Carnot F, Colombo M, et al. (2003) Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J Hepatol 39: 253-261.
10. Tu H, Bonura C, Giannini C, Mouly H, Soussan P, et al. (2001) Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 61: 7803-7810.
11. Yang M, Li Y, Padgett RW, (2005) MicroRNAs: Small regulators with a big impact. Cytokine Growth Factor Rev 16: 387-393.
12. Chen CZ, (2005) MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353: 1768-1771.
13. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, et al. (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537-2545.
14. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, et al. (2008) Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47: 897-907.
15. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, et al. (2008) Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68: 5049-5058.
16. Zhu P, Tan D, Peng Z, Liu F, Song L, (2007) Polymorphism analyses of hepatitis B virus X gene in hepatocellular carcinoma patients from southern China. Acta Biochim Biophys Sin (Shanghai) 39: 265-272.
17. Jiao J, Cao H, Chen XW, Zhou MJ, Liu ZH, et al. (2007) Downregulation of HBX mRNA in HepG2.2.15 cells by small interfering RNAJ. Eur J Gastroenterol Hepatol 19: 1114-1118.
18. Terradillos O, Billet O, Renard CA, Levy R, Molina T, et al. (1997) The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 14: 395-404.
19. Yu YM, Arora A, Min WX, Roifman CM, Grunebaum E, (2009) EdU incorporation is an alternative non-radioactive assay to H-3.thymidine uptake for in vitro measurement of mice T-cell proliferations. J Immunol Methods 350: 29-35.
20. Chehrehasa F, Meedeniya AC, Dwyer P, Abrahamsen G, Mackay-Sim A, (2009) EdU, a new thymidine analogue for labelling proliferating cells in the nervous system. J Neurosci Methods 177: 122-130.
21. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495-500.
22. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P, (1980) Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 286: 533-535.
23. Beasley RP, Hwang LY, Lin CC, Chien CS, (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2: 1129-1133.
24. Thorgeirssonl SS, Grisham JW, (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346.
25. Minami M, Daimon Y, Mori K, Takashima H, Nakajima T, et al. (2005) Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 24: 4340-4348.
26. Chen WN, Oon CJ, Leong AL, Koh S, Teng SW, (2000) Expression of Integrated Hepatitis B Virus X Variants in Human Hepatocellular Carcinomas and Its Significance. Biochem Biophys Res Commun 276: 885-892.
27. Wang Y, Lu Y, Toh ST, Sung WK, Tan P, et al. (2010) Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 53: 57-66.
28. Hou Z, Liu G, Zheng F, Tan D, (2009) HBx gene inducing hepatocellular carcinoma in vivo and its mechanism. J Cent South Univ (Med Sci) 34: 282-287.
29. Liu Y, Zhao JJ, Wang CM, Li MY, Han P, Wang L, et al. (2009) Altered expression profiles of microRNAs in a stable hepatitis B virus-expressing cell line. Chin Med J 122(1): 10-14.
30. Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, et al. (2009) Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is down-regulated. Hepatology Research 39: 786-794.
31. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A, (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res 14: 1902-1910.
32. Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, et al. (1997) Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 150: 81-89.
33. Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M, et al. (2007) Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 54: 2040-2044.
34. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM, (2007) Survivin: a promising tumor biomarker. Cancer Lett 249: 49-60.
35. Lastowska M, Roberts P, Pearson AD, Lewis I, Wolstenholms J, et al. (1997) Promiscuous translocations of chromosome arm 17q in human neuroblastomas. Genes Chromosomes Cancer 19: 143-149.
36. Aschrafi A, Schwechter AD, Mameza AG, Natera-Naranjo O, Gioio AE, et al. (2008) MicroRNA-338 Regulates Local Cytochrome c Oxidase IV mRNA Levels and Oxidative Phosphorylation in the Axons of Sympathetic Neurons. J Neurosci 28: 12581-12590.
37. Huang XH, Chen JS, Wang Q, Chen XL, Wen L, et al. (2011) miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol 225: 463-72.
38. Patil MA, Zhang J, Ho C, Cheung ST, Fan ST, et al. (2006) Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther 5: 111-117.
39. Huang SH, He J, Zhang XL, Bian YH, Yang L, et al. (2006) Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 27: 1334-1340.
40. Hulit J, Lee RJ, Russell RG, Pestell RG, (2002) ErbB-2-induced mammary tumor growth: the role of cyclinD1 and p27kip1. Biochem Pharmacol 64: 827-836.
41. Murillo CA, Rychahou PG, Evers BM (2004) RNAi-mediated inhibition of cyclin D1 decreases colon cancer cell proliferation and MMP protein expression. Journal of the American College of Surgeons 199: 11. Abstract.
42. Ikehara M, Oshita F, Ito H, Ohgane N, Suzuki R, et al. (2003) Expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in small adenocarcinomas of the lung. Oncol Rep 10: 137-139.
43. Sauter ER, Takemoto R, Litwin S, Herlyn M, (2002) p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther 9: 807-812.
44. Klein A, Guhl E, Tzeng YJ, Fuhrhop J, Levrero M, Graessmann M, et al. (2003) HBx causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53. Oncogene 22: 2910-2919.
45. Park SG, Chung C, Kang H, Kim JY, Jung G, (2006) Up-regulation of Cyclin D1 by HBx Is Mediated by NF-κB2/BCL3 Complex through κB Site of Cyclin D1 Promoter. J Biol Chem 281: 31770-31777.
46. Benn J, Schneider RJ, (1995) Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci USA 92: 11215-11219.
47. Bouchard M, Giannakopoulos S, Wang EH, Tanese N, Schneider RJ, (2001) Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway. J Virol 75: 4247-4257.
48. Chenb P, Li Y, Yang L, (2009) Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase. Oncology Reports 22: 1101-1107.
49. Tralhao JG, Roudier J, Morosan S, (2002) Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: An alternative mechanism of HBx-related pathogenesis. PNAS 99: 6991-6996.
50. Lassus P, Ferlin M, Piette J, Hibner U, (1996) Anti-apoptotic activity of low levels of wild-type p53. EMBO J 15: 4566-4573.
51. Chen X, Ko LJ, Jayaraman L, Prives C, (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10: 2438-2451.
52. Murakami S, Cheong JH, Kaneko S, (1994) Human hepatitis virus X gene encodes a regulatory domain that represses transactivation of X protein. J Biol Chem 269: 15118-15123.
53. Misral KP, Mukherji A, Kumar V, (2004) The conserved amino-terminal region (amino acids 1-20) of the hepatitis B virus X protein shows transrepression function. Virus Res 105: 157-165.
54. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, et al. (1997) Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 94: 14707-14712.